A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Completed · Phase 3 · NCT05248893
Conditions: Glabellar Lines
At a glance
- Research payments reported, 2025
- $55,153
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 992
About the trial
- Sponsor
- AbbVie
- Tested
- AGN-151586 (drug)
- Dates
- Started 2022-02-25; completion 2023-06-26
- Results posted
- Yes
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin. The primary purpose of this study is to evaluate the safety of AGN-151586 over up to three treatments of the study drug to improve the appearance of glabellar lines. AGN-151586 is an investigational product being developed for the treatment of GL. Around 940 to 1100 adult participants with moderate to severe GL will be enrolled in the study in approximately 45 sites in the United States. This is an open-label study in which all participants will receive 5 intramuscular AGN-151586 injections to the glabellar complex o…
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $55,153 in research payments for this study in 2025 (2 payments).
Products named: Botox
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Laser & Skin Surgery Center of Indiana $51,336
- Premier Clinical Research $3,817
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.